Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261062 | 1.00 | SLC1A3 (0.51) | SLC1A3SIRT1MMP2MMP9FOLH1 | |
| SCHEMBL5854507 | 0.96 | SLC1A3 (0.52) | SLC1A3SIRT1MMP2MMP9FOLH1 | |
| SCHEMBL5854503 | 0.96 | SLC1A3 (0.52) | SLC1A3SIRT1MMP2MMP9FOLH1 | |
| SCHEMBL5855554 | 0.96 | SLC1A3 (0.52) | SLC1A3SIRT1MMP2MMP9FOLH1 | |
| SCHEMBL29233071 | 0.90 | SIRT1 (0.49) | SLC1A3SIRT1MMP2MMP9ITGB3 | |
| SCHEMBL29233069 | 0.90 | SIRT1 (0.49) | SLC1A3SIRT1MMP2MMP9ITGB3 | |
| SCHEMBL25409269 | 0.88 | TGM2 (0.47) | MMP2MMP9FOLH1ITGB3ITGA2B | |
| SCHEMBL21891962 | 0.84 | SIRT1 (0.61) | SIRT1FOLH1SIRT2 | |
| SCHEMBL11436844 | 0.84 | FAAH (0.55) | SLC1A3SIRT1SIRT2 | |
| SCHEMBL30544863 | 0.83 | TGM2 (0.50) | MMP2MMP9FOLH1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119060325-B | Polylysine rich in 1, 3-dicarbonyl side chains and preparation method and application thereof | 浙江农林大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-119060325-A | Polylysine rich in 1, 3-dicarbonyl side chains and preparation method and application thereof | 浙江农林大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-118215651-A | Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition | 旭化成株式会社 | 2024-06-18 | — | — | CN | disclosed |
| CN-112438905-B | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-112438905-A | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-03-05 | — | — | CN | disclosed |
| CN-110546135-A | Method for producing isocyanate | ASAHI CHEMICAL IND | 2019-12-06 | — | — | CN | disclosed |
| EP-1338588-B1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORP (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7199264-B2 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7030214-B2 | Ureins derived from α, ω, diamino acids and process for their preparation | SOLVAY (SOCIETE ANONYME) (BE) | 2006-04-18 | — | — | US | disclosed |
| EP-0922696-B1 | Urea derivatives of alpha, omega-diaminoacids and peptides | SOLVAY (BE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1338588-A1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORPORATION (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20020058784-A1 | Ureins derived from alpha, omega, -diamond acids and process for their preparation | CALLENS ROLAND (BE) | 2002-05-16 | — | — | US | disclosed |
| US-6310178-B1 | AS THE N-TERMINAL RESIDUE OF BIOLOGICALLY ACTIVE PEPTIDES, E.G, THYROTROPIN RELEASING HORMONE (BY REPLACING THE N-TERMINAL PYROGLUTAMYL GROUP); IMPARTING INCREASED RESISTANCE TO PROTEOLYTIC DIGESTION | SOLVAY, S.A. (BE) | 2001-10-30 | — | — | US | disclosed |
| EP-0633267-B1 | Process for the preparation of alpha-amino acid amide for use in peptide synthesis | SOLVAY (BE) | 2001-09-26 | — | — | EP | disclosed |
| EP-0629612-B1 | Process for the preparation of ureas derived from alpha, omega-diaminoacids | SOLVAY (BE) | 1999-12-01 | — | — | EP | disclosed |
| EP-0922696-A2 | Urea derivatives of alpha, omega-diaminoacids and peptides | SOLVAY (Société Anonyme) (BE) | 1999-06-16 | — | — | EP | disclosed |
| EP-0633267-A1 | Process for the preparation of an alpha-amino acid amide for use in peptide synthesis | SOLVAY (Société Anonyme) (BE) | 1995-01-11 | — | — | EP | disclosed |
| EP-0629612-A1 | Ureas derived from alpha, omega-diaminoacids and process for their preparation | SOLVAY (Société Anonyme) (BE) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | ALAD, AAAS, BCAT1 | SLC1A3 105/4885SIRT1 4595/4885MMP2 2787/4885 |
| US-20020058784-A1 | Ureins derived from alpha, omega, -diamond acids and process for their preparation | UPP1, URB2, UFM1 | SLC1A3 3925/4885SIRT1 4310/4885MMP2 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.